A
AnaCardio
A privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure
About AnaCardio
AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company dedicated to developing novel drugs to treat heart failure. The company focuses on creating innovative inotropic agents that leverage the ghrelin signalling pathway. These agents aim to increase heart muscle contractility and force, thereby boosting cardiac output without causing adverse effects such as tachycardia, arrhythmia, ischemia, or hypotension. AnaCardio's solutions are designed to improve organ function, quality of life, and functional capacity, while reducing the risk of hospitalization and death for heart failure patients.
Read full description
AnaCardio operates in the biopharmaceutical market, primarily serving patients suffering from heart failure. The company employs a clinical-stage business model, advancing its drug candidates through various phases of clinical trials. Revenue generation is anticipated through successful drug development, regulatory approval, and subsequent commercialization, either independently or through partnerships with larger pharmaceutical companies.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Solna kommun, Sweden
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 80.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Seal of Excellence EC, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2025 | $25M | $99M | Industrifonden · Ann-Helene Ljungström · Novo Holdings · Flerie Invest | ↗ |
| SERIES A✓Equity / VC | Jan 2024 | $6.1M | $91M | 3B Future Health Fund · Karolinska Development · Fredrik Ljungström · Industrifonden | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for AnaCardio is 370 monthly website visits, down 66.4% over the last three months. AnaCardio's team grew 4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Karolinska Development
Series A8 investors entered at this stage
Industrifonden
Flerie Invest- FLFredrik Ljungström
3B Future Health Fund- ALAnn-Helene Ljungström
Novo Holdings
Pureos Bioventures
Sound Bioventures
Other known investors2 additional known investors
Karolinska Institute
KI Innovations AB
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AnaCardio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AnaCardio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.